Page 29 Volume 18 - N.3 - 2010

Dor (2010) 18
30. Rahan EJ, Hohmann AG. Cannabinoids as pharmacotherapy for 50. Sayyah M, Hadidi N, Kamalinejad M. Analgesic and anti-inflamma-
Neuropatic Pain: from the bench to the bedside. Neurotherapeutics. tory activity of Lactuca sativa seed extract in rats. J Ethnopharmcol.
2009;6(4):713-5. 2004;92(2-3):325.
31. Lynn B. Capsaicin: actions on nociceptive C fibres and therapeutic 51. Wesołowska A, Nikiforuk A, Michalska K, Kisiel W, Chojnacka-Wójcik
potential. Pain. 1990;41(1):61-9. E. Analgesic and sedative activities on Lactucin and some Lactucin-
32. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain like guaianolides in mices. J Ethnopharmacol. 2006;107(2):254-8.
with topical large-dose Capsaicin: preliminary report. Anesth Analg. 52. Juvin P, Desmond JM. The ancestors of inhalational anesthesia.
1998;86(3):579. Anesthesiology. 2000;93(1):265-9.
33. Hautkappe M, Roizen MF, Toledano A, Roth S, Jeffries JA, Oster- 53. Suleiman RK, Zarga MA, Sabri SS. New withanolides from Man-
meier AM. Review of the effectiveness of Capsaicin for painfull dragora officinarum. Fitoterapia. 2010;81(7):964-8.
cutaneous disorders and neural dysfunction. Clin J Pain. 1998; 54. Belch JJ, Hill A. Evening primrose and borage oil in rheumatologic
14(2):97-106. conditions. Am J Clin Nutr. 2000;71(1):352.
34. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) 55. Darlington LG, Stone TW. Antioxidants and fatty acids in amelioration
therapy for Pain relief: farwell or revival? Clin J Pain. 2008;24(2): of the Rheumatoid Arthritis and related disorders. Br J Nutr.
142-54. 2001;85(3):251-69.
35. Mohr C, Leyendecker S, Mangels I, Machner B, Sander T, Helm- 56. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for
chen C. Central representation of cold-evoked Pain relief in Cap- sleep: a systematic review and meta-analysis. Am J Med.
saicin induced pain: an event-related fMRI study. Pain. 2008;2139 2006;119:1005-12.
(12):416-30. 57. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff
36. Lambert DG. Capsaicin receptor antagonists: a promising new ad- H. Extracts of Valeriana officinalis L.: show ansyolitic and antidepres-
ditation to the Pain clinic. Br J Anaesth. 2009;102(2):153-5. sant effects but neither sedative nor miorelaxants properties. Phyto-
37. Bailey DG, Spence JD, Munoz C, et al. Grapefruit juice – Drug in- medicine. 2008;15(1-2):2-15.
teraction. Br J Pharmacol. 1998;46(2):101-10. 58. International Association for the Study of Pain. Pain terms glossary.
38. Sterling ES, Smith KM. What’s the scope with grapefruit? Orthope- Pain. 1979;6:250.
dics. 2005;28(7):31-4. 59. Kan PC, Liew S. Traditional chinese herbal medicine. Anaesthesia.
39. Sugimoto K, Araki N, Ohmori M, et al. Interaction between grapefruit 2002;57(11):1083-9.
juice and hypnotic drugs: comparison of triazolam and quazepam. 60. Rocha GM, Rocha MEN. Uso popular de plantas medicinais. Saúde
Europ J Clin Pharmacol. 2006;63(3):209. em Ambiente Rev. 2006;1(2):76.
40. Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its 61. França ISX, Sousa JA, Baptista RS, Britto VRS. Medicina Popular:
interaction with various drugs. Nutr J. 2007;6:33. benefícios e malefícios das plantas medicinais. Rev Bras Enferma-
41. Mascus DM, Grollman AP. Ephedra-free is not danger free. Science. gem. 2008;61(2):201-5.
2003;301(5640):1669-71. 62. Hu Z, Yang ZX, Ho PC, et al. Herbs-Drugs Interactions: a literature
42. Young S. Mangosteen for the Cancer patients: facts and myths. J review. Drugs. 2005;65(9):1239.
Soc Integrat Oncol. 2006;4(3):130-44. 63. Nicoletti MA, Júnior MAO, Bertasso CC, Caporossi PY, Tavares AP.
43. Pedraza-Chaverri J, Cárdenas-Rodríguez N, Orozco-Ibarra M, Pér- Principais interacções no uso de medicamentos fitoterápicos. In-
ez-Rojas JM. Medicinal properties of Mangosteen. Food Chem farma. 2007;19(1-2).
Toxicol. 2008;46(10):3227-39. 64. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. In-
44. Bumrunpert A, Kalpravidh RW, Chuang CC, Overman A, Martinez cidence and severity of potential drugs. Arch Int Med. 2004;164(6):
K. Xantone from Mangosteen inhibit inflammation in human mac- 630-6.
rophages and in human adipocytes exposed to macrophages-con- 65. Barnes J. Pharmacovigilance of herbal medicines: a UK perspec-
ditioned media. J Nutr. 2010;140(4):842-7. tive. Drug Saf. 2003;26(12):829-51.
45. Gasper B, Holroyd J. St. John’s wort for depression: a systematic 66. Izzo AA, Ernst E. Interaction between herbal medicines and pre-
review. Arch Int Med. 2000;160:152. scribed drugs: a systematic review. Drugs. 2001;61(15):2163.
46. Yue Q, Bergquist C, Gerden B. Safety of St. John’s wort. Lancet. 67. Goto CS, Feng S-Y, Wiebe RA. How to prevent harmful drug interac-
2000;355:576. tions. Emerg Med. 2008;40(2);25.
47. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. 68. Brusler CA. Herb-Drug interaction: interaction between Ginseng and
The effect of St. John’s wort (Hypericum perforatum) on human prescription medications. Geriatrica. 2005;60(8):16-7.
Cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317. 69. Grossell-Williams M, Simon OR, West ME. The past and present use
48. Gröning R, Breitkreutz J, Müller RS. Physico-Chemical interactions of Plants for Medicine.West Indian Med J. 2006;55(4):217.
between extracts of Hypericum perforatum L. and Drugs. Europ J 70. Heinrich M. Ethnopharmacology in 21 century – grand challenges.
st
Biopharm. 2003;56(2):231. Frontiers Pharmacol. 2010;1(8):1-2.
49. Moschella C, Jaber BL. Interaction between cyclosporine and Hy- 71. WHO Guidelines on safety monitoring of herbal medicines in
pericum perforatum (St. John’s wort) after organ transplantation. Am pharmacovigilance systems. Genebra: World Health Organiza-
Kidney Dis. 2001;38:1105-7. tion; 2004.

DOR

28